Display options
Cite
Otowa-Suematsu N, Sakaguchi K, Nakamura T, et al. Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. Diabetes Ther. 2018;9(5):2067-2079doi: 10.1007/s13300-018-0505-2.
Otowa-Suematsu, N., Sakaguchi, K., Nakamura, T., Hara, K., Kishi, M., Hashimoto, N., Yokota, K., Yoshino, H., Kuroki, Y., Nishiumi, T., Sou, A., Komada, H., Okada, Y., Hirota, Y., Tamori, Y., & Ogawa, W. (2018). Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(5), 2067-2079. https://doi.org/10.1007/s13300-018-0505-2
Otowa-Suematsu, Natsu, et al. "Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 9,5 (2018): 2067-2079. doi: https://doi.org/10.1007/s13300-018-0505-2
Otowa-Suematsu N, Sakaguchi K, Nakamura T, Hara K, Kishi M, Hashimoto N, Yokota K, Yoshino H, Kuroki Y, Nishiumi T, Sou A, Komada H, Okada Y, Hirota Y, Tamori Y, Ogawa W. Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. Diabetes Ther. 2018 Oct;9(5):2067-2079. doi: 10.1007/s13300-018-0505-2. Epub 2018 Sep 11. PMID: 30206903; PMCID: PMC6167300.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2018 Oct;9(5):2067-2079. doi: 10.1007/s13300-018-0505-2. Epub 2018 Sep 11.

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Natsu Otowa-Suematsu, Kazuhiko Sakaguchi, Tomoaki Nakamura, Kenta Hara, Minoru Kishi, Naoko Hashimoto, Kazuki Yokota, Hiroshi Yoshino, Yasuo Kuroki, Tomoko Nishiumi, Anna Sou, Hisako Komada, Yuko Okada, Yushi Hirota, Yoshikazu Tamori, Wataru Ogawa

Affiliations

  1. Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  2. Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. [email protected].
  3. Division of General Internal Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. [email protected].
  4. Department of Diabetes and Endocrine disease, Kita-harima Medical Center, Ono, Japan.
  5. Department of Internal Medicine, Nishiwaki Municipal Hospital, Nishiwaki, Japan.
  6. Department of Diabetes and Endocrinology, Hyogo Brain and Heart Center, Himeji, Japan.
  7. Department of Internal Medicine, Jinkeikai Ishii Hospital, Akashi, Japan.
  8. Department of Internal Medicine, Shinsuma General Hospital, Kobe, Japan.
  9. Department of Internal Medicine, Kobe Century Memorial Hospital, Kobe, Japan.
  10. Department of Diabetes and Endocrinology, Kobe Rosai Hospital, Kobe, Japan.
  11. Division of Creative Health Promotion, Department of Social/Community Medicine and Health Science, Kobe University Graduate School of Medicine, Kobe, Japan.

PMID: 30206903 PMCID: PMC6167300 DOI: 10.1007/s13300-018-0505-2

Abstract

INTRODUCTION: We comprehensively evaluated the effects of combination therapy with insulin glargine and the incretin-based drugs lixisenatide or vildagliptin in Japanese patients with type 2 diabetes.

METHODS: In this 12-week, randomized, open-label, parallel-group, multicenter study (GLP-ONE Kobe), the incretin-based drug sitagliptin was randomly switched to lixisenatide (20 μg/day, n = 18) or vildagliptin (100 mg/day, n = 20) in patients with inadequate glycemic control despite combination therapy with insulin glargine and sitagliptin. The dose of insulin glargine was titrated after the switch to maintain fasting blood glucose at approximately 110 mg/dL. The primary end points of the study were the change in glycosylated hemoglobin (HbA

RESULTS: The change in HbA

CONCLUSION: The combinations of basal insulin and either lixisenatide or vildagliptin have similar efficacies with regard to improvement of glycemic control.

TRIAL REGISTRATION: This trial has been registered with UMIN (No. 000010769).

Keywords: Insulin glargine; Lixisenatide; Vildagliptin

References

  1. Lancet. 2008 Mar 29;371(9618):1073-84 - PubMed
  2. Diabetes Res Clin Pract. 1995 May;28(2):103-17 - PubMed
  3. N Engl J Med. 2009 Oct 29;361(18):1736-47 - PubMed
  4. J Diabetes Investig. 2014 Jul;5(4):445-8 - PubMed
  5. Clin Ther. 2015 Jan 1;37(1):225-241.e8 - PubMed
  6. Clin Ther. 2012 Jun;34(6):1247-1258.e22 - PubMed
  7. Diabetes Care. 2013 Sep;36(9):2489-96 - PubMed
  8. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  9. Diabetes Obes Metab. 2017 Sep;19(9):1252-1259 - PubMed
  10. Cardiovasc Diabetol. 2012 Aug 06;11:92 - PubMed
  11. Endocrine. 2016 Jun;52(3):458-80 - PubMed
  12. Nat Rev Endocrinol. 2012 Dec;8(12):728-42 - PubMed
  13. Am J Med. 2011 Jan;124(1 Suppl):S3-18 - PubMed
  14. Br J Clin Pharmacol. 2016 Jul;82(1):301-14 - PubMed
  15. Diabetes Obes Metab. 2014 Jul;16(7):636-44 - PubMed
  16. Diabetes Obes Metab. 2010 Jun;12(6):495-509 - PubMed
  17. Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):125-32 - PubMed
  18. Vasc Health Risk Manag. 2016 Aug 18;12:337-40 - PubMed
  19. J Clin Invest. 2014 Oct;124(10):4473-88 - PubMed
  20. Pharmacol Rep. 2015 Feb;67(1):24-31 - PubMed
  21. J Diabetes Investig. 2015 Mar;6(2):192-200 - PubMed
  22. Lancet. 2012 Jun 16;379(9833):2262-9 - PubMed
  23. Diabetes Obes Metab. 2016 Mar;18(3):203-16 - PubMed
  24. Sci Rep. 2016 Oct 19;6:35633 - PubMed
  25. Diabetes Obes Metab. 2012 Oct;14(10):910-7 - PubMed
  26. J Clin Transl Endocrinol. 2014 Apr 11;1(2):31-37 - PubMed
  27. Diabetes Obes Metab. 2014 Sep;16 Suppl 1:33-40 - PubMed

Publication Types